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Abstract
Background—Peritoneal dialysis (PD) is the preferred dialysis modality for many end-stage
renal disease (ESRD) patients in the US. However, in sharp contrast to the high rates of PD use in
other industrialized countries, utilization of PD in the US is low and declining. PD availability is a
necessary condition for PD utilization; however, little is known about the availability and
geographic distribution of PD services. This study describes trends in the regional supply of PD
services among dialysis facilities between 1995 and 2003.
Study design—Longitudinal cohort study.
Setting and participants—Non-federal outpatient dialysis facilities treating ESRD patients in
the US using data from the US Renal Data System.
Predictors—Annual ESRD patient and dialysis facility composition in hospital referral regions.
Outcome—Annual proportion of dialysis facilities offering PD treatment services in hospital
referral regions.
Results—The average proportion of facilities offering PD services in hospital referral regions
was 56% in 1996, which declined to 47% in 2003. There was geographic variation in PD services,
with greater PD availability in metropolitan cities (compared to rural regions) and the Northeast
(relative to the South and Midwest). Variation in PD availability was not explained by disease
trends or patient characteristics believed to be important for PD use. An increasing regional
presence of chain-affiliated facilities was associated with less PD supply.
Limitations—Accuracy of patient registry data, inability to account for consolidation of PD
services among chain providers, sensitivity of results to definition of regional markets.
Conclusions—The small and declining availability of PD seems counterintuitive given its
demonstrated appeal to patients and payers. Further research is needed to further investigate
dialysis facilities’ role in the underutilization of a potentially useful therapy.
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BACKGROUND
In 2006, over 500,000 Americans were treated for end-stage renal disease (ESRD) at an
annual cost of $33.6 billion.1 Growth in the ESRD population and the limited availability of
kidneys for transplantation have increased utilization and federal outlays for dialysis
services. Although peritoneal dialysis (PD) offers an effective, convenient, and less
expensive alternative to hemodialysis (HD), its use in the US has been low: PD use peaked
at 14% of all incident ESRD patients in 1985, and has continuously declined since 1995 to a
current rate of 6.2%.1 This rate is far below other North American, Asian, and European
countries where 20–81% of ESRD patients were treated with PD.2
This low utilization of PD in the US is inconsistent with the demonstrated appeal of PD to
patients, providers, and payers. Studies have demonstrated that PD is preferred by many
dialysis patients.3–6 In terms of optimal clinical outcomes, cost-effectiveness and quality of
life, 33–40% of nephrologists believe PD is appropriate for half their patients. Medicare, the
primary payer of health care services for ESRD patients in the US, spent an average $18,562
less per PD patient than for each HD patient in 2006.1 Medicare provides financial
incentives for facilities to provide PD services by reimbursing facilities the same prospective
reimbursement (i.e., a composite rate) for either PD or HD treatment, even though PD is less
costly for facilities.7, 8 In light of this evidence, the low and declining utilization of PD in
the US is perplexing.
Much of the empirical evidence on the declining use of PD has focused on individual
determinants of PD utilization and has not explained the low and declining use of PD.9–11 In
spite of clinical improvements among incident PD patients, the decline in PD use has not
been attributable to patient characteristics.11 Although some differences across dialysis
organizations have been observed,12 little attention has been paid to the availability of PD
services at dialysis facilities even though its supply may influence physicians’ and patients’
choice of treatment. Ultimately, the availability of PD services is the necessary condition
from which PD utilization can occur. Earlier studies cross-sectionally examined PD supply
and found a tendency for facilities offering PD to target areas with patient populations
appropriate for PD therapy.13–15 Yet it is not clear where PD services are available and how
this distribution of supply has changed because few studies have examined the dynamics of
PD services longitudinally.16–18
In this study, we employed longitudinal and geographic methods to describe trends in the
regional supply of PD services between 1995 and 2003. We also tested hypotheses of
whether PD was available in areas where it may be needed most. Since many incident
dialysis patients prefer PD when informed of their dialysis options,3, 4, 19 we examined
trends in PD supply in relation to area characteristics with the greatest potential for PD
demand such as rural locations and regions with high incidence of ESRD, as well as areas in
which ESRD patients are more likely to have characteristics associated with PD use such as
White, young, and employed ESRD populations.5, 20
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Study design and data
We conducted a longitudinal cohort study of all ESRD patients and dialysis facilities in the
US between 1995 and 2003. The study sample included non-federal outpatient dialysis
facilities located in the US and District of Columbia as well as all prevalent ESRD patients
receiving any ESRD-related service during the study period. The data for this study come
from multiple sources, but the principal source of information on ESRD providers and
patients came from US Renal Data System (USRDS).
Dialysis facility characteristics, treatment service offerings, and operating statistics came
from the Centers for Medicare and Medicaid Services Annual Facility Survey (CMS-2744,
USRDS-FACILITY file). We accounted for facilities that opened and closed during the
study period, and paid particular attention to facilities that were sold or purchased by other
organizational entities. CMS assigns new provider identification numbers to facilities
undergoing changes in ownership and, as a result, facilities that were acquired may have
multiple provider identification numbers, even though their physical location and staffing
remain intact. We tracked changes in ownership, obtained facility addresses and information
regarding facility affiliation with any chain organization by augmenting USRDS data with
information from the CMS Provider of Service file. From these merged data, we improved
the accuracy and quality of our facility-level data by removing invalid or duplicate
submissions and obtaining more information on chain affiliation. To retain as many facility
observations as possible for analysis, missing facility survey data (< 0.50% of facilities) was
imputed using the value of the preceding or subsequent year (or the average of both, if
available).
Patient characteristics were obtained from information in the Medical Evidence Report
(CMS-2728). Since a new report was required for all patients beginning or re-entering
ESRD service, we tracked changes in patient characteristics and residence over time. Data
on ESRD patients between 1995 and 2003 was culled from two USRDS files. The
PATIENTS file contains information on patients’ first date of ESRD service, demographic
information, and date of death. Patient movement over time was tracked using patient zip
codes from the RESIDENC file.
Demographic characteristics were obtained from several sources. County-level demographic
statistics from the Area Resource File were converted to the zip code-level based on land-
area weighting. Healthcare provider census data was obtained from the American Hospital
Association’s Annual Hospital Survey and American Medical Association’s Physician
Masterfile.
All zip code-level dialysis facility, ESRD patient, and demographic data were aggregated to
generate region-level statistics based on Hospital Referral Regions (HRRs) for each year of
the study period. HRRs may be a more valid measure of healthcare markets than municipal
designations (e.g., counties, metropolitan statistical areas) because HRR boundaries are
based on actual patient utilization, thereby reflecting the geographic extent of healthcare
markets for tertiary care.21 HRRs are particularly appropriate for studies of ESRD services
because ESRD patients receive a significant amount of specialized non-dialysis care in
tertiary settings.22 Furthermore, the larger geographic area of HRRs better reflect PD service
areas, as PD patients are likely to travel outside county boundaries for their care. Data on zip
code assignments to HRRs (n=306) were obtained from geographic boundary files from the
Dartmouth Atlas of Health Care.23
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Our outcome of interest was regional availability of PD services, which we defined as the
annual percentage of dialysis facilities in an HRR that reported offering PD treatment
services (either continuous ambulatory or continuous cyclic) in the USRDS-FACILITY file.
We were unable to measure the extent of PD availability because there are no observable
capacity parameters for PD as there are for HD (e.g., number of stations). For the purposes
of this descriptive analysis, the proportion of facilities offering PD therapy is appropriate
because it is observable; measures availability (i.e., potential utilization); and accounts for
differences in the size of regions and dialysis markets.
Potential demand for PD is approximated by several patient characteristics attributed to PD
use.5, 20 ESRD incidence was based on date of ESRD onset and HRR residence for a given
year and calculated as the number of new ESRD patients per 10,000 general population in
each HRR. The remaining patient characteristics were aggregated to the HRR level and
measured as a percentage among prevalent ESRD patients. We calculated the percentages of
White, African American, Asian, other non-White, and Hispanic patients to represent patient
race and ethnicity. The percentage of non-elderly patients represented the proportion of
ESRD patients in an HRR younger than 65 years of age. Similarly, the percentage of
employed ESRD patients was based on report of either full- or part-time patient
employment.
Our analysis also accounted for facility composition in regional markets, including the
proportion of facilities that were freestanding units (versus hospital-based), for-profit
owned, affiliated with any chain organization, experienced a change in ownership during the
year, and were located in urban locations. General market characteristics, such as per capita
income, healthcare provider density, and dialysis market competition, served as control
variables. Healthcare provider density was operationalized using 1) the number of hospital
beds and 2) full time equivalent nephrologist supply per HRR square mile. Because the two
measures were highly correlated with one another (r= 0.96), we used factor analysis to
construct a single, composite measure.24, 25 Dialysis market competition was calculated
using the Herfindahl index, which is equal to the sum of the square of each dialysis facility’s
market share (i.e., based on the number of dialysis patients unique to each facility).26 For
ease of interpretation, this variable was coded in reverse such that an index value of −1
represented concentrated or monopolistic markets and values approaching 0 characterized
unconcentrated, competitive dialysis markets.
Analysis
Univariate statistics were used to 1) generate maps of geographic distributions of PD
availability, by HRR, and 2) compare changes in PD supply to patient and facility
composition in markets. Multivariate analysis was also conducted using SAS version 9.1
(SAS Institute, www.sas.com) to examine the extent to which PD service availability was
related to ESRD patient and facility compositions in the markets. We used generalized
estimating equations (GEE) to account for correlations among repeated observations to yield
consistent population-averaged parameter estimates.27 All covariates were lagged by one
year from the dependent variable. We used Wald chi-square statistics to test the joint
significance of groups of covariates in the multivariate model (e.g., patient and facility
characteristics). Several additional variables (e.g., proportion of pre-ESRD erythropoietin
use, average number of comorbid conditions and average BMI among ESRD patients) were
considered, but dropped from the multivariate model because of their high correlations with
other patient population attributes that caused multicollinearity in the analysis. The study
was approved by the Institutional Review Boards of the University of North Carolina at
Chapel Hill and Duke University Health System.
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Changes in the supply of PD services over time
The supply of PD services varied over time and by geographic region. Temporally, the
proportion of dialysis facilities offering PD services averaged 51–56% between 1995 and
1999, but declined to 47% in 2003 (Figure 1). Although the total numbers of facilities
offering PD services increased over time, PD growth was not proportional to the overall
growth of the dialysis industry. The observed downward trend in regional PD availability
was due to a more rapid increase in the total number of dialysis facilities entering the
dialysis market throughout the study period (not shown). Geographically, PD supply was
generally greater in metropolitan cities and the Northeast, and less available in rural regions
and in the South and Midwest. Exceptions to these geographic trends over time appear in
HRRs in Texas, which experienced growth of PD, and the North Central states, where the
proportion of facilities offering PD therapies diminished throughout the study period (not
shown).
Association between changes in PD supply and demand for dialysis services
Although there was wide variation in regional markets’ ESRD patient composition (Table
1), overall HRR-level ESRD prevalence and patient demographic trends favorable for PD
use were either stable or increased as PD supply declined. The inverse relationships found in
unadjusted annual trends (Table 2) suggests that PD supply did not appear responsive to
characteristics known to favor PD use among ESRD patients.
PD service availability appeared to be more associated with organizational characteristics of
dialysis facilities. The steady decline of PD service availability occurred at a time of marked
increases in the proportions of for-profit, chain-affiliated, and freestanding (non-hospital
based) dialysis facilities across HRRs. These trends reflected a period of growth of
freestanding facilities and changes in facility ownership to for-profit and chain-affiliated
entities.
In terms of the association between PD service availability and ESRD patient and provider
characteristics (Table 3), PD was less available in HRRs with a greater representation of
non-White ESRD patients. Compared to HRRs with a higher proportion of White ESRD
patients, a 10 percentage point increase in African American ESRD patients within HRRs
was associated with 2.6% fewer dialysis facilities with PD services in HRRs (β= −0.26; p=
0.0001) and 6.2% among “other non-White” ESRD patients (β= −0.62; p= 0.004). A 10
percentage point increased presence of chain-affiliated facilities in HRRs was associated
with 0.4% less PD service availability (β= −0.04; p= 0.08). However, a similar increase
among dialysis facilities in urban settings was associated with 1.1% more PD availability in
HRRs (β= 0.11; p= 0.0006).
DISCUSSION
To the best of our knowledge, this is the first study to describe temporal trends in PD service
availability in dialysis facilities. In contrast to prior studies, we examined the
underutilization of PD by exploring the availability of PD services, which is a precondition
of PD utilization and observed outcomes. The data presented here fills a gap in the literature
by exploring trends in PD service offerings among dialysis facilities over time, the extent of
geographic variation in PD service availability, and the factors related to the availability of
PD services.
We found that there has been a low and declining proportion of dialysis facilities offering
PD services over time and that the availability of PD services has varied by geography. We
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also found that variations in PD service availability did not appear to be explained by
disease incidence or patient characteristics associated with increased PD utilization. This
finding is consistent with prior patient-level analyses of PD utilization in that declines in
either PD availability or utilization could not be fully explained by other patient factors over
time.11 The negative association we found between the percentages of non-White ESRD
patients and PD supply aligns with our expectations. However, the negative associations we
found between ESRD incidence, non-elderly, and employed patient populations on PD
availability were surprising because it suggests that PD services may not be available to
patients who have been known to use and benefit from it.
Given Medicare’s equal payment for dialysis treatments and lower facility costs associated
with PD, we expected the potential profitability of PD to increase its availability, especially
among for-profit, chain-affiliated, and freestanding facilities that dominate the US dialysis
industry. However, the only significant relationship was between increasing proportions of
chain-affiliated facilities and less regional PD supply. This finding is consistent with extant
literature13 that suggests that consolidation and increased market share of chain
organizations in the dialysis industry contributed to the decline in PD services. Although we
did not find ownership change to be related to PD service availability, it is still possible that
chains have standardized service modalities across affiliated sites or consolidated their PD
service lines into a few units that take on a large number of PD patients,28 especially in
regions with a high density of dialysis facilities. The negative correlation we found between
the percentage of chain-affiliated dialysis facilities and PD supply (r= −0.20, not shown)
suggests that this may be the case. However, due to the lack of reliable information needed
to formally examine the extent of PD consolidation, these claims remain untested.29 Future
research, incorporating detailed data on facilities’ affiliation with specific chain
organizations, may elucidate our understanding of the provision of PD services among chain
dialysis providers.
Our study has several limitations. First, although our study showed that a smaller percentage
of dialysis facilities offered PD services during the study period, facilities may have
increased their capacity for PD therapy. However, the possibility of increased capacity could
not be assessed using our data. In view of the declining rate of PD use among ESRD
patients, we suspect that the likelihood of capacity increase was small and that, if it
occurred, the increase would be limited to a small number of dialysis facilities. Second, it is
also possible that chain organizations have consolidated PD programs, reducing the number
of facilities offering PD without affecting PD availability. Sole use of USRDS chain-specific
affiliation, which identifies only the nine largest chain organizations, ignores the potential
significance of smaller or regional chains that may bias our findings. Combining USRD and
CMS data allowed us to determine affiliation with any chain organization, but did not allow
for reliable assessment of chain-specific effects or PD consolidation over time. Third, the
accuracy of reported data and data collection methods may affect the results of our analysis.
For example, because facilities and physicians are required to submit patient documentation
only when a patient begins a new treatment modality or transfers to a new facility, changes
in patients’ employment or comorbidities may not always be accurate. However, the
USRDS patient registry data is the best known source of comprehensive data on ESRD
patients at the national level. Fourth, our findings may be sensitive to the definition of
regional markets. Because counties and hospital services areas do not adequately reflect
health service use, particularly for PD services, we chose HRRs to better reflect cross-
county travel to dialysis facilities’ PD services. Although HRRs may be too large, PD-
specific geographic markets do not exist. Finally, there are myriad factors contributing to the
declining supply of PD services that were not examined. For example, the availability of
clinicians (e.g., nephrologists, nurses, and surgeons) with PD training and experience could
Wang et al. Page 6













not be readily measured, but are important factors in dialysis facilities’ decision to provide
PD services.30–32
Despite these limitations, our study contributes to the literature on the low use of PD in the
US. Our evidence of geographic variations and declining regional supply of PD therapy
seems counterintuitive to the evidence on the clinical and individual factors driving PD
preference and use. The trends presented here are also particularly timely and raise concerns
about costs, quality, and patient access to ESRD care. The diminishing supply of PD
therapies across regions suggests possible missed opportunities in achieving cost savings in
the Medicare ESRD program, the primary payer for over 90% of the nation’s ESRD care.1
Medicare’s overall ESRD costs are generally lower in regions where PD is more prevalent
than where PD is less common.22 PD is less expensive and more cost-effective than HD in
terms of dialysis costs and, after including hospitalizations due to dialysis, overall Medicare
ESRD costs.7, 33–35 These cost savings persist even among patients who begin PD in the
first year of dialysis and later switch to HD.36 Recent analysis conservatively estimated that
an increase in PD use from 8% to 15% would save Medicare over $1.1 billion in Medicare
over five years.37
The declining availability of PD services may limit quality of ESRD care. There is evidence
that 1) PD patients report better quality of life and fewer negative aspects of life than HD
patients;19, 38, 39 2) up to 40% of nephrologists believe PD is an appropriate and cost-
effective modality for half of their ESRD patients;40, 41 and 3) when informed of all their
treatment options, many pre-ESRD and dialysis patients prefer PD.3, 4, 19 However, only one
quarter of patients ever recall the option of PD being discussed when dialysis was
initiated.42 Even when pre-ESRD is detected early enough to allow physicians and patients
time to develop a treatment plan, the limited availability of PD services may adversely affect
modality choice43 and inhibit the alignment of ESRD care with patient preferences.
Lastly, the declining supply of PD therapies raises concern about disparities in access to PD.
One advantage of PD is less frequent travel for dialysis maintenance, which may appeal to
patients lacking adequate transportation or living long distances from dialysis facilities.
Consistent with prior research, we found less PD supply in rural regions.14 It is possible that
distance to facilities may not be a significant barrier to PD use, since the required monthly
visits may not prevent rural ESRD patients from receiving PD treatment in urban locales.
However, we also found 25 HRRs (8.2% of all HRRs), in regions largely characterized as
rural, with small (if any) metropolitan cities, lacked any facility offering PD service in any
given year. Although urbanicity was a constant predictor of PD availability, the lack of PD
service offerings in rural regions is problematic. Approximately 75% of dialysis facilities in
all time periods of the study were located in metropolitan locations. The dearth of PD
service may compromise access for ESRD patients for whom PD is appropriate, such as
patients lacking adequate vascular access or those intending to preserve vascular access for
later use.44, 45 Considering the increasing rates of ESRD incidence among non-elderly
patients and minority patients with diabetes,1 it was surprising to find lower PD supply in
markets with higher proportions of these potentially PD-appropriate ESRD subpopulations.
Additional analysis (not shown) revealed that high ESRD prevalent regions with more non-
White ESRD patients had lower PD supply. While PD may not be appropriate for all ESRD
patients, it should be an available treatment option.46–48 To address these concerns and
inform efforts to improve patients’ access to PD treatment, further study with patient-level
data could explore the extents to which modality choice is available and PD services are
accessible to various subgroups of ESRD patients. Since ESRD patient characteristics do not
seem to adequately explain regional PD supply, it will be important to further examine the
forces contributing to the declining availability and utilization of a potentially beneficial
therapy.
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Table 1
Descriptive Statistics of Regional PD Supply and Hospital Referral Region Composition, 1995–2003
N= 2,754 HRR-years Mean ± SD Range
% Facilities with any PD service 51.0 ± 26.4 (0, 100)
ESRD patient composition
 Incidence (per 10,000 pop) 3.4 ± 1.57 (0.7, 17.2)
 Prevalence (per 10,000 pop) 18.3 ± 8.0 (3.4, 80.9)
 Race
  % White 71.7 ± 20.7 (14.4, 99.6)
  % African American 23.4 ± 21.3 (0, 79.7)
  % Asian 2.4 ± 5.9 (0, 83.0)
  % Other race 2.5 ± 5.0 (0, 42.1)
  % Hispanic ethnicity 5.0 ± 8.9 (0, 73.3)
 % Non-elderly 59.2 ± 5.7 (29.5, 75.1)
 % Employed 7.0 ± 3.9 (0, 20.7)
Dialysis facility composition
 % For profit-owned 68.7 ± 31.3 (0, 100)
 % Chain affiliation 60.4 ± 32.7 (0, 100)
 % Freestanding 74.5 ± 30.2 (0, 100)
 % Urban 70.0 ± 30.7 (0, 100)
 % ownership change 4.7 ± 13.5 (0, 100)
Other regional characteristics
 Per capita income (1,000s) 21.7 ± 4.7 (8.7, 47.8)
 Healthcare provider density −0.1 ± 0.5 (−0.2, 7.0)
  Hospital density (beds) 2.0 ± 10.0 (0.002, 146.3)
  Nephrologist density 0.02 ± 0.1 (0, 1.6)
 Dialysis market competition −0.3 ± 0.3 (−1.0, −0.01)
Notes:
1. Incidence and prevalence defined as ESRD patients per 10,000 general population in each HRR throughout the year (i.e., period
incidence).
2. Healthcare provider density is a composite measure of regional supply of hospital beds and nephrologists per square mile.
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